Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8587021 | 0.94 | — | — | |
| SCHEMBL27716555 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4ECXCR4MAPTHRH3 | |
| SCHEMBL13350455 | 0.80 | CXCR4 (0.43) | ALDH1A1KDM4ECXCR4HRH3 | |
| SCHEMBL30098982 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KDM4ECXCR4 | |
| SCHEMBL15508578 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4ECXCR4MAPTHRH3 | |
| SCHEMBL8520734 | 0.77 | PRCP (0.36) | ALDH1A1 | |
| SCHEMBL4986922 | 0.76 | KMT2A (0.43) | ALDH1A1 | |
| SCHEMBL661180 | 0.76 | — | — | |
| SCHEMBL26981315 | 0.76 | — | — | |
| SCHEMBL3801626 | 0.75 | PRCP (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105745778-B | Generate the lithium-sulfur cell of electric current | 联邦科学和工业研究机构 | 2019-06-28 | — | — | CN | disclosed |
| US-9981957-B2 | Synthetic process | THE UNIVERSITY OF LIVERPOOL (GB) | 2018-05-29 | — | — | US | disclosed |
| US-9943554-B2 | Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170107208-A1 | SYNTHETIC PROCESS | THE UNIVERSITY OF LIVERPOOL (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20160317588-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | SYNAPSIN PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9259419-B2 | Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2043642-B1 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | SYNAPSIN PHARMACEUTICALS INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140086998-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8524741-B2 | Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing cognitive and physical performance | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20100056572-A1 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | SYNAPSIN PHARMACEUTICALS, INC. | 2010-03-04 | — | — | US | disclosed |
| EP-2043642-A2 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | Synapsin Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008720-A2 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | SYNAPSIN PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056572-A1 | COMPOSITIONS AND METHODS RELATING TO SOLENOPSINS AND THEIR USES IN TREATING NEUROLOGICAL DISORDERS AND ENHANCING PHYSICAL PERFORMANCE | ACHE, SMN1; SMN2, NLN | ALDH1A1 678/4885KDM4E 2973/4885CXCR4 4265/4885 |
| US-20160317588-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | ACHE, SMN1; SMN2, NLN | ALDH1A1 678/4885KDM4E 2973/4885CXCR4 4265/4885 |
| US-20140086998-A1 | Compositions And Methods Relating To Solenopsins And Their Uses In Treating Neurological Disorders And Enhancing Physical Performance | ACHE, SMN1; SMN2, NLN | ALDH1A1 678/4885KDM4E 2973/4885CXCR4 4265/4885 |
| US-20170107208-A1 | SYNTHETIC PROCESS | PIR, SRM, SMS | ALDH1A1 1225/4885KDM4E 1105/4885CXCR4 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.